Rocío Isabel
Rodríguez Macías
Catedrática de Universidad
Hospital Universitario de Donostia
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (18)
2023
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
Hepatology, Vol. 73, Núm. 6, pp. 2311-2325
2020
-
A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma
Cancers, Vol. 12, Núm. 6
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis
Cells, Vol. 9, Núm. 3
-
Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach
Cancers, Vol. 12, Núm. 6, pp. 1-30
2019
-
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy
Hepatology, Vol. 70, Núm. 4, pp. 1246-1261
-
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 108-122
-
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Hepatology, Vol. 70, Núm. 2, pp. 547-562
2018
-
The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477
2017
-
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
Hepatology, Vol. 66, Núm. 4, pp. 1125-1143
2016
-
Bile acids in physiology, pathology and pharmacology
Current Drug Metabolism, Vol. 17, Núm. 1, pp. 4-29
-
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
Nature Reviews Gastroenterology and Hepatology, Vol. 13, Núm. 5, pp. 261-280
2014
-
Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development
Molecular Cancer Research, Vol. 12, Núm. 1, pp. 91-100